Maintaining an Effective CAPA Program and Using Risk Assessment Tools: Current Trends - Webinar by GlobalCompliancePanel

Date	Dec 3, 2013
Time	01:00 PM EDT
Cost	$225.00
Online

Overview: CAPA programs are critical for any manufacturer. FDA considers your program the immune system for your site business unit and determines how healthy or unhealthy you are. 

Industry is now using various risk-based approaches and tools to set-up, deploy and maintain their CAPA programs to help with the decision making process. Understand the emphasis on analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems...and the use of appropriate statistical methodology where necessary to detect recurring quality problems. This session provides an overview on identifying recommended practices to improve, streamline, refine, retool…and develop, deploy and maintain a viable and sustainable CAPA system. Learn that a well written policy and procedure on setting up and maintaining your system is just the first part of the process…now you need to monitor your system because CAPA is your immune system and will determine how healthy or unhealthy or business site is. Learn some of the new practices being used on how to conduct the CAPA investigation and the use these tools. 

Areas Covered in the Session:

• How to use FMEA effectively and calculating Risk Priority Numbers: How to Use the Criteria
• How to facilitate a product complaint investigation as part of your CAPA program
• What is a closed-loop investigation…cradle to grave approach
• How to conduct an investigation using a well-written CAPA policy and procedure
• Understand and comprehend what FDA is looking for in meeting minimum expectations…no band-aid solutions
• Why risk assessment and risk-based approaches, FMEA, FTA, HACCP, etc., are now the expectation in terms of good business practice
• Establish a priority system as related to major versus minor or high risk versus low risk classifications…to support your decisions
• Develop and deploy escalation rules and criteria to facilitate decision-making process
• Understand what it takes to conduct a “quality” investigation to ascertain the root cause
• Review and discuss recent CAPA red flags and FDA enforcement actions

Who Will Benefit:This webinar will provide valuable assistance and guidance to all regulated companies that are preparing to use or are currently using risk-based tools for CAPA investigations and closing out investigations in a timely manner. The employees who will benefit include:

• All levels of Management for all departments and those who desire a better understanding or a "refresh" overview
• QA/QC/CAPA Coordinators/CAPA Specialists
• Regulatory Affairs and Compliance
• Engineering/Technical Services/Operations
• Consultants

David R. Dills, Regulatory Affairs & Compliance Consultant currently provides regulatory, compliance and quality consultative services for medical device and pharmaceutical/combination manufacturers, and also has an accomplished record with more than 24 years of experience with Class I/II/III medical devices, In Vitro diagnostics, and pharmaceuticals in the areas of Regulatory Affairs, Compliance and Quality Systems. 

NetZealous LLC,
DBA GlobalCompliancePanel 
161 Mission Falls Lane,
Suite 216, Fremont, CA 94539, USA          
USA Phone:800-447-9407
Fax: 302-288-6884
webinars@globalcompliancepanel.com    
http://www.globalcompliancepanel.com

Event Link - http://bit.ly/1cqzeVX